MedTrace Logo

Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome

NCT05737030 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-02-10

No results posted yet for this study

Summary

Study to test the effect of the drug "L-ornithine.L-aspertate" (LOLA) on microorganisms in the digestive tract in patients with liver cirrhosis (damage of the liver due to liver disease)

Conditions

  • Cirrhosis

Interventions

DRUG

L-ornithine L-aspartate

Amino acid combination

Sponsors & Collaborators

  • CBmed Ges.m.b.H.

    collaborator OTHER

  • Medical University of Graz

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-06
Primary Completion
2024-07-23
Completion
2025-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05737030 on ClinicalTrials.gov